The main aim of our study was to investigate the specific contribution of a 9-valent human papillomavirus vaccine (9vHPV) to the recurrence risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women vaccinated post-excision. Therefore, we conducted a retrospective monocentric cohort study in women aged 22-49 years undergoing conization between 2014 and 2023. The 9vHPV-vaccinated women were matched to unvaccinated women for age and follow-up duration in a 1:2 ratio to eliminate allocation bias. The risk of CIN2+ recurrence was estimated by the incidence rate ratio using Poisson regression with adjustment for comorbidities, smoking status, nulliparity, CIN grade, positive cone margin, and HPV genotypes. The CIN2+ recurrence rates in 147 women enrolled in the analysis were 18 and 2 cases per 100,000 person-days for unvaccinated and vaccinated women, respectively, during a mean follow-up period of 30 months (±22 months). A reduction in CIN2+ recurrences by 90% (95% confidence interval: 12-99%) was documented in 9vHPV-vaccinated participants compared to women undergoing only surgical excision. Moreover, vaccinated women with a positive cone margin showed a 42% (though non-significant) reduction in relapse (p = .661). Full post-conization vaccination with the 9vHPV contributed to an additional reduction in the risk of CIN2+ recurrence. This finding is consistent with current knowledge and suggests a high adjuvant effect of the 9vHPV vaccine.

Center of Ambulatory Gynecology and Primary Care Brno Czech Republic

Department of Anesthesia and Intensive Medicine 1st Faculty of Medicine Charles University and Military University Hospital Prague Czech Republic

Department of Epidemiology and Biostatistics 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Hygiene 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Obstetrics and Gynecology Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Laboratory for Atherosclerosis Research Center for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Petráš M, Dvořák V, Lomozová D, Máčalík R, Neradová S, Dlouhý P, Malinová J, Rosina J, Lesná IK.. Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression. Sex Transm Infect. 2023;99(8):561–6. doi:10.1136/sextrans-2023-055793. PubMed DOI PMC

Capra G, Giovannelli L, Matranga D, Bellavia C, Guarneri MF, Fasciana T, Scaduto G, Firenze A, Vassiliadis A, Perino A. Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: a referral hospital-based study in Sicily. Hum Vaccines Immunother. 2017;13(8):1839–43. doi:10.1080/21645515.2017.1319026. PubMed DOI PMC

Bosco L, Serra N, Fasciana T, Pistoia D, Vella M, Di Gregorio L, Schillaci R, Perino A, Calagna G, Firenze A, et al. Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations. Sci Rep. 2021;11(1):4096. doi:10.1038/s41598-021-83639-6. PubMed DOI PMC

Del Pino M, Martí C, Torras I, Henere C, Munmany M, Marimon L, Saco A, Torné A, Ordi J. HPV vaccination as adjuvant to conization in women with cervical intraepithelial neoplasia: a study under real-life conditions. NATO Adv Sci Inst Se. 2020;8(2):245. doi:10.3390/vaccines8020245. PubMed DOI PMC

Casajuana-Pérez A, Ramírez-Mena M, Ruipérez-Pacheco E, Gil-Prados I, García-Santos J, Bellón-Del Amo M, Hernández-Aguado JJ, De La Fuente-Valero J, Zapardiel I, Coronado-Martín PJ. Effectiveness of prophylactic human papillomavirus vaccine in the prevention of recurrence in women conized for HSIL/CIN 2–3: the VENUS study. NATO Adv Sci Inst Se. 2022;10(2):288. doi:10.3390/vaccines10020288. PubMed DOI PMC

Henere C, Torné A, Llupià A, Aldea M, Martí C, Glickman A, Saco A, Marimon L, Manzotti C, Rakislova N, et al. HPV vaccination in women with cervical intraepithelial neoplasia undergoing excisional treatment: insights into unsolved questions. NATO Adv Sci Inst Se. 2022;10(6):887. doi:10.3390/vaccines10060887. PubMed DOI PMC

Paradkar PH, Joshi JV, Mertia PN, Agashe SV, Vaidya RA. Role of cytokines in genesis, progression and prognosis of cervical cancer. Asian Pac J Cancer Prev. 2014;15(9):3851–64. doi:10.7314/APJCP.2014.15.9.3851. PubMed DOI

Saftlas AF, Spracklen CN, Ryckman KK, Stockdale CK, Penrose K, Ault K, Rubenstein LM, Pinto LA. Influence of a loop electrosurgical excision procedure (LEEP) on levels of cytokines in cervical secretions. J Reprod Immunol. 2015;109:74–83. doi:10.1016/j.jri.2015.01.002. PubMed DOI

Zhuang C-L, Lin Z-J, Bi Z-F, Qiu L-X, Hu F-F, Liu X-H, Lin B-Z, Su Y-Y, Pan H-R, Zhang T-Y, et al. Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response. Emerging Microbes Infect. 2021;10(1):365–75. doi:10.1080/22221751.2021.1891002. PubMed DOI PMC

Abdulaziz AMA, You X, Liu L, Sun Y, Zhang J, Sun S, Li X, Sun W, Dong Y, Liu H, et al. Management of high-grade squamous intraepithelial lesion patients with positive margin after LEEP conization: a retrospective study. Medicine (Baltimore). 2021;100(20):e26030. doi:10.1097/MD.0000000000026030. PubMed DOI PMC

Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(5):31. doi:10.4103/sja.SJA_543_18. PubMed DOI PMC

Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat- Simul Comput. 2009;38(6):1228–34. doi:10.1080/03610910902859574. DOI

Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)? Gynecol Oncol. 2013;130(2):264–8. doi:10.1016/j.ygyno.2013.04.050. PubMed DOI

Grzes B, Heimrath J, Ciszek M. Minimally invasive surgery with the complementing immunotherapy in the treatment of intraepithelial neoplasia of cervix in women of child-bearing age. Onkol Pol. 2011;14:125–30.

Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A, Svelato A, Bertacca G, Lombardi S, Joura EA. SPERANZA project: HPV vaccination after treatment for CIN2+. Gynecol Oncol. 2018;151(2):229–34. doi:10.1016/j.ygyno.2018.08.033. PubMed DOI

Petrillo M, Dessole M, Tinacci E, Saderi L, Muresu N, Capobianco G, Cossu A, Dessole S, Sotgiu G, Piana A. Efficacy of HPV vaccination in women receiving LEEP for cervical dysplasia: a single institution’s experience. NATO Adv Sci Inst Se. 2020;8(1):45. doi:10.3390/vaccines8010045. PubMed DOI PMC

Chen M, Li C, Cui Q, Zhou C, Chen P, Yao S. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: a prospective observational study in China. Eur J Obstet Gyn R B. 2023;286:10–15. doi:10.1016/j.ejogrb.2023.04.014. PubMed DOI

Pieralli A, Bianchi C, Auzzi N, Fallani MG, Bussani C, Fambrini M, Cariti G, Scarselli G, Petraglia F, Ghelardi A. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease. Arch Gynecol Obstet. 2018;298(6):1205–10. doi:10.1007/s00404-018-4926-y. PubMed DOI

Calagna G, Maranto M, Paola C, Capra G, Perino A, Chiantera V, Cucinella G. ‘Secondary prevention’ against female HPV infection: literature review of the role of carrageenan. Expert Rev Anti Infect Ther. 2020;18(9):865–74. doi:10.1080/14787210.2020.1770082. PubMed DOI